Phase II Proof-of-concept Study of APD421

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01303978
Recruitment Status : Completed
First Posted : February 25, 2011
Last Update Posted : September 25, 2012
Information provided by (Responsible Party):
Acacia Pharma Ltd

February 24, 2011
February 25, 2011
September 25, 2012
February 2011
July 2012   (Final data collection date for primary outcome measure)
Complete Response [ Time Frame: 24 hours after cisplatin dosing ]
No emesis or use of rescue medication
Same as current
Complete list of historical versions of study NCT01303978 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Phase II Proof-of-concept Study of APD421
Open-label, Ascending-dose, Phase II Study to Determine the Minimum Effective Dose of APD421 in the Prevention of Cisplatin-induced Nausea and Vomiting
Evaluation of efficacy of APD421 in preventing nausea and vomiting caused by cisplatin
Not Provided
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Chemotherapy-induced Nausea and Vomiting
Drug: APD421
Single dose
Experimental: APD421 starting dose
Intervention: Drug: APD421
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2012
July 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female patients ≥ 18 years of age
  2. Ability and willingness to give written informed consent
  3. Patients scheduled to receive, on day 1 of their chemotherapy, a first cisplatin chemotherapy infusion at a dose of 50 mg/m2 or greater
  4. Karnofsky performance score ≥ 60%
  5. Adequate cardiac, hepatic and renal function

    • QTc interval < 500 ms
    • Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) < 5 x upper limit normal (ULN)
    • Bilirubin < 3 x ULN
    • Creatinine < 2 x ULN
  6. Adequate haematological function

    • Haemoglobin ≥ 9 g/dL
    • White blood count ≥ 3.0 x 109/L
    • Platelet count ≥ 100 x 109/L
  7. For females of child-bearing potential: ability and willingness to use a highly effective form of contraception (e.g., abstinence from sexual intercourse, surgical sterilisation (of subject or partner) or a double-barrier method of contraception such as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in conjunction with partner's use of a condom) during the study and for a period of at least 48 hours afterwards.

Exclusion Criteria:

  1. Patients scheduled to receive, prior to or in the 24 hours after cisplatin, any chemotherapeutic agent with a high or moderate emetic risk, see Appendix 4.
  2. Patients scheduled to receive paclitaxel or docetaxel
  3. Patients undergoing abdominal or pelvic irradiation within 48 hours prior to screening or scheduled to receive abdominal or pelvic irradiation between screening and 24 hours after cisplatin administration
  4. Patients receiving APD421 for any indication within the last 2 weeks
  5. Patients who are allergic to APD421 or any of the excipients of APD421
  6. Patients with a pre-existing vestibular disorder
  7. Patients being treated with regular anti-emetic therapy including corticosteroids
  8. Patients receiving inhaled corticosteroids, unless started more than one month prior to the expected date of study entry
  9. Patients being treated with medications which could induce torsades de pointes, including Class Ia antiarrhythmic agents such as quinidine, disopyramide, procainamide; Class III antiarrhythmic agents such as amiodarone and sotalol; and other medications such as bepridil, cisapride, thioridazine, methadone, IV erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin
  10. Patients being treated with xxx
  11. Patients receiving benzodiazepines, unless on a stable dose for at least one month prior to the expected date of study entry
  12. Patients with pre-existing nausea or vomiting in the 24 hours before receiving cisplatin chemotherapy, e.g. anticipatory emesis
  13. Patients who are pregnant or breast feeding
  14. Patients with a history of alcohol abuse
  15. Patients with pre-existing, clinically significant cardiac arrhythmia
  16. Any other concurrent disease or illness that, in the opinion of the investigator makes the patient unsuitable for the study
  17. Patients who have participated in another study within the previous 28 days
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Denmark,   United Kingdom
Not Provided
Not Provided
Acacia Pharma Ltd
Acacia Pharma Ltd
Not Provided
Not Provided
Acacia Pharma Ltd
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP